Exclusive: Ready to exit 'quiet mode,' joint entity Ventyx debuts its immune modulator pipeline with $114M round
In the crazy world of biotech financing, precocious startups are scoring big checks from investors with some often laughably early data. Now, a California immune modulation player is ready to uncloak with a nine-figure down payment in hand and an unusually advanced pipeline.
Encinitas-based Ventyx Biosciences has scored a $114 million equity investment to try three different immune modulator targets in the clinic, one of which is already squared up for a Phase II study in ulcerative colitis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.